# US 2016/0235773 A1 · Antidepressant combination drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235773 A1
- Document ID: US20160235773A1
- Status: Published application
- Kind: A1
- Application number: 15/029,885
- Filed: 2014-10-14
- Published: 2016-08-18
- Earliest claimed: 2013-10-15
- Assignees: Nishizaki Bioinformation Research Institute
- Applicants: Nishizaki Bioinformation Research Institute
- Inventors: Tomoyuki NISHIZAKI
- Web page: https://patentgrep.com/patent/US20160235773A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A23J 7/00: Phosphatide compositions for foodstuffs, e.g. lecithin
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23J: PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The combined use of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine affords a superior anti-depressive action, an improving effect on the cognitive function associated with depression, an improving effect on the stress-induced suppression of Akt activation, and a suppressive action on the stress-induced GSK-3β activation. Therefore, the present invention can provide an antidepressant combination drug, an agent for improving cognitive function associated with depression, an agent for improving stress-induced suppression of Akt activation and an agent for suppressing stress-induced GSK-3β activation.

## Claims

### Claim at position 1

-6. (canceled)

### Claim 7

A method of improving stress-induced suppression of Akt activation, comprising treating cells or tissues with 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.

### Claim 8 (depends on 7)

The method according to claim 7, wherein stress-induced GSK-3β activation is suppressed.

### Claim 9 (depends on 7)

A method according to claim 7, which leads to prophylaxis, improvement, and/or treatment of depression.

### Claim 10 (depends on 8)

A method according to claim 8, which leads to prophylaxis, improvement, and/or treatment of depression.

### Claim 11

A method of improving stress-induced suppression of Akt activation, comprising administering an effective amount of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and an effective amount of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine in combination to a target in need thereof.

### Claim 12 (depends on 11)

A method according to claim 11, which leads to prophylaxis, improvement, and/or treatment of depression.

### Claim 13 (depends on 11)

A method according to claim 11, wherein stress-induced GSK-3β activation is suppressed.

### Claim 14 (depends on 13)

A method according to claim 13, which leads to prophylaxis, improvement, and/or treatment of depression.